SLN-124 is under clinical development by Silence Therapeutics and currently in Phase II for Polycythemia Vera. According to GlobalData, Phase II drugs for Polycythemia Vera have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SLN-124’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SLN-124 is under development for the treatment of hereditary hemochromatosis, alpha/beta thalassemia, polycythaemia vera. The therapeutic candidate is composed of the oligonucleotide conjugated with N-acetylgalactosamine (GalNAc). It is administered through subcutaneous route. It is developed based on GalNAc-siRNA technology and mRNAi GOLD platform . It acts by tageting transmembrane protease serine 6 (TMPRSS6). It was also under development for myelodysplastic syndrome.
Silence Therapeutics overview
Silence Therapeutics, formerly SR Pharma plc is a developer of therapeutics that channels gene silencing to cure life-threatening diseases. The company’s pipeline products include SLN124, and SLN360. Its SLN360 is developed for the treatment of cardiovascular disease with high Lp(a) in risk of heart disease and heart stroke, and SLN124 for e-Thalassaemia and myelodysplastic syndrome. Silence Therapeutics also provides RNA interface that include short interfering RNA (siRNA) and messenger RNAs (mRNA). The company collaborates with pharmaceutical, biotechnology companies and academic research institutions. It operates in Germany, the US, and the UK. Silence Thrapeutics is headquartered in London, Greater London, the UK.
For a complete picture of SLN-124’s drug-specific PTSR and LoA scores, buy the report here.